Business Description
BioVie Inc. is a US-based medical research company focused on developing treatments for brain disorders and serious liver conditions. Its two main drug candidates are BIV201, targeting fluid buildup caused by liver cirrhosis, and NE3107, which is being tested as a potential treatment for Alzheimer's disease, Parkinson's disease, and long COVID. Founded in 2013 and headquartered in Carson City, Nevada, the company was previously called NanoAntibiotics Inc. before rebranding in 2016.
